This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Inman BA. Bladder Sparing Methods in Muscle-Invasive Bladder Cancer. Grand Rounds in Urology. October 2025. Accessed Jan 2026. https://grandroundsinurology.com/bladder-sparing-methods-in-muscle-invasive-bladder-cancer/
Summary
In this presentation, Brant A. Inman, MD, MS, FRCSC, Chin-Hardie Chair of Urologic Oncology and Professor of Urology and Oncology, Western University, London, Canada, examines the use of bladder sparing strategies in muscle-invasive bladder cancer, focusing on when preservation may be reasonable, why it may be chosen, and under what circumstances radical cystectomy remains preferred. Dr. Inman emphasizes that decision-making begins with understanding disease biology, staging accuracy, and patient-specific factors rather than applying a single uniform approach. He describes how patient age, comorbidity, and overall treatment tolerance influence therapy selection and explains that the balance between oncologic control and quality of life strongly shapes clinical discussion.
Dr. Inman explains that radical cystectomy is widely viewed as the standard treatment, but he acknowledges that some patients may achieve meaningful outcomes with bladder preservation when selection is thoughtful. He spends significant time discussing what makes bladder preservation more or less reasonable, including tumor characteristics and realistic expectations about success. He notes that bladder sparing strategies require careful initial tumor management, realistic assessment of disease burden, coordinated care, and willingness to proceed to cystectomy if outcomes are not adequate.
Dr. Inman highlights the importance of counseling and communication, explaining that patients must understand the commitment involved with bladder preservation and that this approach requires close monitoring. Dr. Inman discusses the potential benefits and drawbacks of surveillance cystectomy, partial cystectomy, systemic therapy alone, and radiation. He acknowledges that chemoradiation is a reasonable option for older and less fit patients with MIBC, although he is wary about its use in younger and fitter patients.
Dr. Inman reinforces that bladder preservation is not a universal substitute for cystectomy, but remains an important option when carefully applied. He encourages clinicians to approach decision-making thoughtfully, remain realistic about potential outcomes, and stay informed about ongoing research and new techniques.
About The 12th Urology Today Conference:
Presented by chair Ryan P. Terlecki, MD, FACS, the 12th Urology Today conference was designed to keep urologists, urologic oncologists, and other healthcare providers educated on the most pertinent issues in urology practices. Areas of focus included urologic oncology, men’s health and reconstruction, female urology, pediatric urology, kidney stones and related conditions, and methods of providing the best care amidst the required logistics of the business side of medicine.
